The online version of this article (doi:10.1186/1477-7819-10-28) contains supplementary material, which is available to authorized users.
The authors declare that they have no competing interests.
PG: carried out material and data acquisition, did literature search, drafted the manuscript. EP: participated in the design of the study and performed the statistical analysis AB: carried out the immunohistochemistry studies, and review mmanuscript. IP: carried out the immunohistochemistry studies EB: participated in study design, data interpretation drafted and edited the manuscript. DS: carried out the immunohistochemistry studies and drafted the manuscript. NA: carried out the immunohistochemistry studies PT: proposed, designed and coordinated the study. All authors read and approved the final manuscript.
To investigate the expression of E-cadherin, beta-catenin and topoisomerase-II alpha and examine their clinical relevance in liposarcomas.
The expression of E-cadherin, beta-catenin and topoisomerase II alpha was examined immunohistochemically on formalin-fixed paraffin-embedded tissue specimens from 71 patients who underwent surgical treatment for liposarcomas of the extremities or the retroperitoneum in two major cancer reference centres between 1990 and 2000. Detailed medical notes were available for all patients who were followed for median 82 months (range 5 to 215 months). Obtained expression data were weighted against clinical and pathology parameters of clinical relevance.
Patients were mostly male (59%), median age was 56 years for the liposarcomas of the extremities and 60 years for the retroperitoneal liposarcomas. The tumours were of diverse histology, grade and size (median diameters 7 and 17 cm for tumours of the extremities and retroperitoneum respectively). Expression of β-catenin protein was weakly detected in 15 cases (21.1%). Similarly weak expression of topoisomerase II-alpha was detected in 14 (19.7%) cases of which only two had more than 20% of tumor cells stained positive. E-cadherin was not detected in the studied cohort of liposarcomas. We did not detect associations between the expression of the above proteins by liposarcoma cells and clinical outcome.
Liposarcomas do not express E-cadherin, which matches the absence of epithelioid differentiation in this sarcoma subtype, and have low topoisomerase II-alpha expression, which justifies to some extend their resistance to anthracycline-based chemotherapy.
Karavasilis V, Seddon BM, Ashley S, Al-Muderis O, Fisher C, Judson I: Significant clinical benefit of first-line palliative chemotherapy in advanced soft-tissue sarcoma: retrospective analysis and identification of prognostic factors in 488 patients. Cancer. 2008, 112 (7): 1585-1591. 10.1002/cncr.23332. CrossRefPubMed
Fritz B, Schubert F, Wrobel G, Schwaenen C, Wessendorf S, Nessling M, Korz C, Rieker RJ, Montgomery K, Kucherlapati R: Microarray-based copy number and expression profiling in dedifferentiated and pleomorphic liposarcoma. Cancer Res. 2002, 62 (11): 2993-2998. PubMed
Moon RT: Wnt/beta-catenin pathway. Sci STKE. 2005, 2005 (271): cm1-10.1126/stke.2712005cm1. PubMed
Kase S, Sugio K, Yamazaki K, Okamoto T, Yano T, Sugimachi K: Expression of E-cadherin and beta-catenin in human non-small cell lung cancer and the clinical significance. Clin Cancer Res. 2000, 6 (12): 4789-4796. PubMed
Gogou PN, Batistatou A, Pakos EE, Apostolikas N, Stefanou D, Tsekeris PG: E-cadherin, b-catenin and topoisomerase II expression in rhabdomyosarcomas. J BUON. 2009, 14 (2): 323-324. PubMed
Yoo J, Park S, Kang CS, Kang SJ, Kim BK: Expression of E-cadherin and p53 proteins in human soft tissue sarcomas. Arch Pathol Lab Med. 2002, 126 (1): 33-38. PubMed
Sakamoto A, Oda Y, Adachi T, Saito T, Tamiya S, Iwamoto Y, Tsuneyoshi M: Beta-catenin accumulation and gene mutation in exon 3 in dedifferentiated liposarcoma and malignant fibrous histiocytoma. Arch Pathol Lab Med. 2002, 126 (9): 1071-1078. PubMed
Hsu PK, Li AF, Wang YC, Hsieh CC, Huang MH, Hsu WH, Hsu HS: Reduced membranous beta-catenin protein expression is associated with metastasis and poor prognosis in squamous cell carcinoma of the esophagus. J Thorac Cardiovasc Surg. 2008, 135 (5): 1029-1035. 10.1016/j.jtcvs.2007.11.007. CrossRefPubMed
Chikamori K, Grozav AG, Kozuki T, Grabowski D, Ganapathi R, Ganapathi MK: DNA Topoisomerase II Enzymes as Molecular Targets for Cancer Chemotherapy. Curr Cancer Drug Targets. 2010
Rody A, Karn T, Ruckhaberle E, Muller V, Gehrmann M, Solbach C, Ahr A, Gatje R, Holtrich U, Kaufmann M: Gene expression of topoisomerase II alpha (TOP2A) by microarray analysis is highly prognostic in estrogen receptor (ER) positive breast cancer. Breast Cancer Res Treat. 2009, 113 (3): 457-466. 10.1007/s10549-008-9964-x. CrossRefPubMed
- Clinicopathologic study of E-cadherin/beta-catenin complex, and topoisomerase-II in a series of 71 liposarcoma cases
- BioMed Central
Neu im Fachgebiet Chirurgie
Mail Icon II